Affect Therapeutics, a gamified mental health startup, raised a $26 million Series B round led by Allumia Ventures, CEO Kristin Muhlner tells Axios Pro exclusively.
Why it matters: While many companies sell to employers, commercial payers or directly to consumers, Affect works primarily with Medicaid recipients.
